Numerate and Intellikine, Inc. Conclude Research Collaboration to Discover Selective Inhibitors Against PI3 Kinase Alpha  
8/11/2010 9:03:33 AM

SAN BRUNO & LA JOLLA, Calif.--(BUSINESS WIRE)--Numerate, Inc. and Intellikine, Inc. today announced the successful conclusion of their research collaboration to discover novel small molecule compounds targeting the PI3K/mTOR signaling pathway. The collaboration combined Intellikine’s unique capabilities in x-ray crystal structure-guided medicinal chemistry and drug discovery with Numerate’s powerful computational drug design platform to identify potent, selective and drug-like inhibitors of PI3 kinase alpha, an important target in cancer therapy.